Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 20/20 | 1.00 |
| ▸ | KDR | P35968 | 1/20 | 0.49 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15910495 | 0.93 | SYK (0.89) | SYKKDRAURKB | |
| SCHEMBL15910741 | 0.93 | SYK (1.00) | SYKKDRAURKB | |
| SCHEMBL15911003 | 0.92 | SYK (1.00) | SYKKDRAURKB | |
| SCHEMBL15910860 | 0.91 | SYK (0.83) | SYKKDRAURKB | |
| SCHEMBL15910977 | 0.90 | SYK (0.82) | SYKKDRAURKB | |
| SCHEMBL16253434 | 0.89 | SYK (0.80) | SYK | |
| SCHEMBL16253436 | 0.88 | SYK (0.78) | SYKKDRAURKB | |
| SCHEMBL16253466 | 0.87 | SYK (0.80) | SYKKDRAURKB | |
| SCHEMBL16253463 | 0.87 | SYK (0.76) | SYKKDRAURKB | |
| SCHEMBL16253445 | 0.85 | SYK (0.74) | SYKKDRAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | claimed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | claimed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | claimed |
| WO-2023178094-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | WO | claimed |
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | claimed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | claimed |
| EP-2762476-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | claimed |
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION | 2025-06-12 | — | — | US | disclosed |
| EP-4493188-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | Purdue Research Foundation (US) | 2025-01-22 | — | — | EP | disclosed |
| CN-119300822-A | Spleen tyrosine kinase inhibitors, compositions, and methods of use | 普渡研究基金会 | 2025-01-10 | — | — | CN | disclosed |
| CN-113166177-B | Boron-containing PDE4 inhibitors | 辉瑞公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-3861001-B1 | BORON CONTAINING PDE4 INHIBITORS | PFIZER (US) | 2023-12-13 | — | — | EP | disclosed |
| WO-2023178094-A2 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | PURDUE RESEARCH FOUNDATION (US) | 2023-09-21 | — | — | WO | disclosed |
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-9145414-B2 | 1,2,4-triazine-6-carboxamide derivative | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2015-09-29 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-11-20 | — | — | US | disclosed |
| EP-2762476-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | Taiho Pharmaceutical Co., Ltd. (JP) | 2014-08-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250186432-A1 | SPLEEN TYROSINE KINASE INHIBITOR, COMPOSITION, AND METHODS OF USE | SYK, BTK, G6PD | SYK 1/4885KDR 639/4885AURKB 1409/4885 |
| US-20140343038-A1 | 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE | SYK, BTK, JAK2 | SYK 1/4885KDR 147/4885AURKB 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.